BUZZ-OS Therapies rises after cancer therapy meets main goal in mid-stage trial

Shares of drug developer OS Therapies OSTX.A rise 56.5% to $6.46 premarket

Co says its experimental immunotherapy met the main goal of a mid-stage trial to treat a type of bone cancer

Co says the therapy, OST-HER2, met the main goal of delaying the recurrence of the cancer by 12 months, compared to the historical comparable group

Co says all patients who achieved the 12-month event-free survival goal are alive

OST-HER2 was safe and well-tolerated in the study, OSTX says

The therapy is being tested to prevent lung metastatic osteosarcoma, a type of recurrent bone cancer that has spread to the lungs

Co says with these results, it is preparing to engage with U.S. FDA on "an accelerated pathway for approval"

"We do not expect to have to treat additional patients as part of this process with FDA," OSTX adds

Stock up 65.7% since its market debut in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))